Download PDFPDF

ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Re: Is ITPA genotyping predictive for the development of side effects to AZA?
    • Jolanda M van Dieren, PhD student
    • Other Contributors:
      • Hanneke A.J. van Vuuren, Ernst J. Kuipers, Bettina E. Hansen, Johannes G. Kusters, Edward E.S. Nieuwenhuis, C. Janneke van der Woude

    Dear Editor,

    In response to the comments of Duley et al. to our letter published in GUT 2005 we would like to make some additional remarks.

    First of all, Duley et al. conclude that our study had a retrospective character, but this is not correct. This is a longitudinal cohort study in which all patients with IBD visiting our out-patient department were included. These patients were followed prospectively fo...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Is ITPA genotyping predictive for the development of side effects to AZA?
    • John A Duley, Senior Scientist
    • Other Contributors:
      • Anthony M. Marinaki, Monica Arenas, and Timothy H. J. Florin

    Dear Editor

    In a retrospective study of patients with inflammatory bowel disease, van Dieren et al recently reported the absence of correlation between genotypes for both inosine triphosphate pyrophosphatase (ITPA) thiopurine methyltransferase (TPMT) with any side effects to azathioprine (AZA) (Gut 2005;54:1664). This contrasts with two other studies. A rigorous prospective study recently published has demonstrat...

    Show More
    Conflict of Interest:
    None declared.